Raw Materials CAS 104987-11-3 Tacrolimus Pharmaceutical Tacrolimus Powder Purity Tacrolimus

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Dsung-Tacrolimus
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Tacrolimus
• Name: Tacrolimus Powder
• Appearance: White or Almost White Crystalline Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 104987-11-3
• Mf: C44h69no12
• MW: 804.031
• Melting Point: 113-115 C
• Boiling Point: 871.7 C at 760 Mmhg
• Density: 1.19
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 500kg/Month

Product Description

Raw Materials CAS 104987-11-3 Tacrolimus Pharmaceutical Tacrolimus Powder Purity Tacrolimus

 

Product Description

Product Details

Product Name	Tacrolimus
CAS No.	104987-11-3
MF	C44H69NO12
MW	804.031
Appearance and shape	White or almost white crystalline powder

Tacrolimus is a macrolide isolated from Streptomyces spp. It has a strong immunosuppressive effect, binding specifically to and inhibiting calmodulin phosphatase activity and inhibiting IL-2 signaling transcription, thereby inhibiting T-cell activation, TNF-α, IL-1β and IL-6 production and T-cell-dependent B-cell proliferation. Compared with cyclosporine, another calmodulin phosphatase inhibitor, tacrolimus inhibits T-cell activation more strongly and has fewer adverse effects.

Application & Function

1. Tacrolimus is a macrolide antibiotics. Immunosuppressants. Same mechanism of action as cyclosporine, mainly inhibits the synthesis of interleukin-2. Used for rejection of organ transplants
2. A macrolide that binds to FK506 binding protein (FKBP) to form a complex that reduces peptidyl prolyl isomerase activity in T cells.
3. FK-506 (Tacrolimus) is a macrolide immunosuppressive drug that is mainly used after allogeneic organ transplant to reduce the activity of the patient's immune system
4. Tacrolimus for use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart.

Specification